Gilead, Cipla Settlement Blocks Copies of Biktarvy HIV Drug

Gilead Sciences Inc. ended its Biktarvy patent lawsuit with Cipla Ltd., reaching a settlement that bars US copies of the HIV therapy until April 2036.

Gilead reached similar settlements last month with Lupin Ltd. and Laurus Labs Ltd., wrapping up all remaining disputes in the consolidated case. It announced the finalized deals in a filing Monday with the US Securities and Exchange Commission and in consent judgments in the US District Court for the District of Delaware.

• The settlements with Cipla were formalized in separate consent judgments approved Monday by Judge Maryellen Noreika for Biktarvy’s adult and pediatric doses ...